The global nuclear medicine market size is expected to reach USD 34.51 billion by 2030, registering a CAGR of 11.69% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic diseases such as cancer & thyroid is anticipated to drive market growth. The impending approval of multiple radiopharmaceutical therapeutics during the forecast period will be a major driver for the market. For instance, in March 2022, Novartis AG received approval for Pluvicto (Lu 177) for the treatment of adult patients with prostate cancer.

According to the Pan American Health Organization (PAHO), in 2022, globally around 20 million new cases of cancer are estimated to be diagnosed, and around 10 million deaths occurred due to this disease. Factors like changing lifestyle, unhealthy diet, and less awareness about oral hygiene in low and middle-income countries is the most common cause of the prevalence of cancer.

Increasing adoption of nuclear medicine products in diagnosis and the approval of new generators to help increase the supply of radionuclides is expected to drive growth. For instance, in November 2021, EZAG received the Brazilian Health Authority Regulatory Agency’s (ANVISA) approval for GalliaPharm in Brazil. It is a gallium-68 generator used to extract the positron-emitting isotope of gallium from a source of decaying germanium-68 for making G68 dotatate injection. This is the first and only gallium generator approved for pharmaceutical use in Brazil. The approval of such products contributes to the market growth in developing markets.

In light of the COVID-19 pandemic, the market was moderately impacted. A survey was conducted for reactor-based medical isotopes by International Atomic Energy Agency (IAEA) during the second quarter of 2020 to assess the continuity of the supply chain during the COVID-19 crisis. It was revealed that major producers continued with production in line with IAEA safety standards, as their operations were categorized as essential by their respective governments.

List of Key Players in the Nuclear Medicine Market

• GE Healthcare
• Jubilant Life Sciences Ltd
• Nordion (Canada), Inc.
• Bracco Imaging S.P.A
• The institute for radioelements (IRE)
• NTP Radioisotopes SOC Ltd.
• The Australian Nuclear Science and Technology Organization
• Eczac?ba??-Monrol
• Lantheus Medical Imaging, Inc
• Eckert & Ziegler
• Mallinckrodt
• Cardinal Health 

Request a free sample copy or view report summary: Nuclear Medicine Market Report

Nuclear Medicine Market Report Highlights

• By product type, the SPECT segment held the largest share of the diagnostics market due to low cost, high accuracy, and wide usage in different applications.
• The PET segment is expected to grow lucratively over the forecast period due to the approval & launch of new products such as PYLARIFY PET imaging agent for prostate cancer.
• By application, the oncology segment dominated the market in 2023.
• North America dominated the market with a share of 42.96% in 2023, owing to increased awareness about current treatment therapies, favorable reimbursement policies, and improved patient affordability.
• The Asia Pacific region is expected to be the fastest-growing region considerably in the future due to the rising prevalence of chronic diseases, rising geriatric population, and approval of new products during the forecast period.

Nuclear Medicine Market Report Scope

Related Press Release@ Nuclear Medicine Industry Analysis

Nuclear Medicine Market Segmentation

Grand View Research has segmented the global nuclear medicine market on the basis of on product, application, end-use, and region:

Nuclear Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)

• Diagnostics
  • SPECT
    • TC-99m
    • TL-201
    • GA-67
    • I-123
    • Others
  • PET
    • F-18
    • SR-82/RB-82
    • PYLARIFY (piflufolastat F 18)
    • Illuccix (gallium Ga 68 gozetotide)
    • Others
  • Therapeutics
    • Alpha Emitters
      • RA-223
      • Others
    • Beta Emitters
      • I-131
      • Y-90
      • SM-153
      • Re-186
      • Lu-177
      • Others
    • Brachytherapy
      • Cesium-131
      • Iodine-125
      • Palladium-103
      • Iridium-192
      • Others

Nuclear Medicine Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cardiology
  • SPECT
  • PET
  • Therapeutic Applications
• Neurology
• Oncology
• Thyroid
  • SPECT
  • Therapeutic Applications
• Lymphoma
• Bone Metastasis
  • SPECT
  • Therapeutic Applications
• Endocrine Tumor
• Pulmonary Scans
• Urology
• Other

Nuclear Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals
• Diagnostic Centers
• Others

Nuclear Medicine Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • S.
  • Canada
  • Mexico
• Europe
  • Germany
  • K.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Explore Horizon, the world's most expansive market research database